AD
Elite in Dengue Fever

Dr. Anna P. Durbin

The Johns Hopkins Hospital
Baltimore, MD
Elite
 in Dengue Fever
Specialties:Infectious Disease
Experience:36 Years
Clinical Trials:Currently Recruiting for 2 Trials
Accepts:New PatientsMedicare
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Anna P. Durbin's experience treating your condition:
About Dr. Anna P. Durbin

Anna Durbin is an Infectious Disease expert in Baltimore, Maryland. Durbin has been practicing medicine for over 36 years and is rated as an Elite expert by MediFind in the treatment of Dengue Fever. She is also highly rated in 13 other conditions, according to our data. Her top areas of expertise are Dengue Fever, Viral Hemorrhagic Fever, Arbovirosis, and West Nile Virus Infection. She is licensed to treat patients in Maryland. Durbin is currently accepting new patients.

Her clinical research consists of co-authoring 146 peer reviewed articles and participating in 32 clinical trials in the past 15 years. In particular, she has co-authored 59 articles and participated in 25 clinical trials in the study of Dengue Fever.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Anna P. Durbin it is best to call her office and ask if your insurance is accepted.

Accepts Medicare
Call to see if your plan is accepted.
Locations
1800 Orleans St, Baltimore, MD 21287
Background & Education
Graduate Institution
Wayne State University School Of Medicine, 1987
Specialties
Infectious Disease
Licenses
Internal Medicine in MD
Hospital Affiliations
The Johns Hopkins Hospital
Howard County General Hospital
Languages Spoken
English
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

32 Clinical Trials
Phase I Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM)
Enrollment Status: Recruiting
Publish Date: September 28, 2022
Intervention Type: Other, Biological
Study Phase: Phase 1
A Phase 2a, Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of Repeated Oral Doses of JNJ-64281802 Against Dengue Serotype 3 Infection in a Dengue Human Challenge Model in Healthy Adult Participants
Enrollment Status: Recruiting
Publish Date: May 12, 2022
Intervention Type: Drug
Study Phase: Phase 2
Phase I Evaluation of the Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults
Enrollment Status: Completed
Publish Date: June 03, 2022
Intervention Type: Biological
Study Drug: rZIKV/D4-Delta-30-713 Live Attenuated Vaccine
Study Phase: Phase 1
Evaluation of the Efficacy of the Live Attenuated Tetravalent Dengue Vaccine Against DENV-2 and DENV-3 Challenge
Enrollment Status: Completed
Publish Date: January 18, 2020
Intervention Type: Biological
Study Phase: Phase 1
Phase I Evaluation of the Safety and Immunogenicity of an Investigational Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naïve Adults 50 - 70 Years of Age
Enrollment Status: Completed
Publish Date: April 02, 2018
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1 Evaluation of the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30
Enrollment Status: Completed
Publish Date: March 08, 2018
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1 Evaluation of the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2
Enrollment Status: Completed
Publish Date: February 28, 2018
Intervention Type: Biological
Study Phase: Phase 1
Evaluation of the Clinical and Immune Response Generated by Heterologous Attenuated Dengue Virus Infection
Enrollment Status: Completed
Publish Date: February 08, 2018
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1 Evaluation of the Safety and Immunogenicity of a Booster Dose of TV003 Administered 12 Months After Initial Vaccination With TV003
Enrollment Status: Completed
Publish Date: June 14, 2017
Intervention Type: Biological
Study Phase: Phase 1
Phase 1 Study of the Safety and Immunogenicity of a 2-Dose Regimen of West Nile/Dengue 4-3´Δ30 Chimeric Virus Vaccine (WN/DEN4Δ30), a Live Attenuated Vaccine for West Nile Encephalitis, in Flavivirus-naïve Adults 50-65 Years of Age
Enrollment Status: Completed
Publish Date: February 01, 2017
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1 Evaluation of the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With Attenuated DENV-2, rDEN2∆30-7169
Enrollment Status: Completed
Publish Date: February 01, 2017
Intervention Type: Biological
Study Phase: Phase 1
A Phase I Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Tetravalent Recombinant Subunit Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)
Enrollment Status: Completed
Publish Date: April 04, 2016
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1 Evaluation of the Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV003 to Protect Against Infection With Attenuated DENV-2, rDEN2∆30-7169
Enrollment Status: Completed
Publish Date: December 15, 2015
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1 Evaluation of the Safety and Immunogenicity of rDEN2Δ30-7169, a Live Attenuated Monovalent Dengue Virus Vaccine
Enrollment Status: Completed
Publish Date: December 15, 2015
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1 Evaluation of the Safety and Immunogenicity of the Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine Admixtures TV003 and TV005 in Healthy Flavivirus-Naïve Adult Subjects
Enrollment Status: Completed
Publish Date: August 20, 2015
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1 Evaluation of the Safety and Immunogenicity of the Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine Admixtures TV003 and TV005 in Healthy Flavivirus-experienced Adult Subjects
Enrollment Status: Completed
Publish Date: August 20, 2015
Intervention Type: Biological
Study Phase: Phase 1
A Phase I Dose Comparison Study of the Safety and Immunogenicity of rDEN3-3'Ddelta30, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 3
Enrollment Status: Completed
Publish Date: January 03, 2013
Intervention Type: Biological
Study Phase: Phase 1
Phase 1 Study of the Safety and Immunogenicity of rDEN4delta30-200,201, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 4
Enrollment Status: Completed
Publish Date: January 03, 2013
Intervention Type: Biological
Study Phase: Phase 1
A Phase I Evaluation of the Safety and Immunogenicity of the rDEN1∆30 Dengue Serotype 1 Vaccine Given at a Single Dose of 101 PFU in Healthy Flavivirus-naïve Adult Subjects
Enrollment Status: Completed
Publish Date: January 03, 2013
Intervention Type: Other, Biological
Study Phase: Phase 1
Phase 1 Study of the Safety and Immunogenicity of a 2-Dose Regimen of West Nile/Dengue 4-3'delta30 Chimeric Virus Vaccine (WN/DEN4delta30), a Live Attenuated Vaccine for West Nile Encephalitis
Enrollment Status: Completed
Publish Date: January 03, 2013
Intervention Type: Biological
Study Phase: Phase 1
Safety and Immunogenicity of a 2-Dose Regimen of rDEN2/4Δ30 Dengue Vaccine With Boosting at 4 Versus 6 Months
Enrollment Status: Completed
Publish Date: January 03, 2013
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1 Evaluation of the Safety and Immunogenicity of Five Admixtures of TetraVax-DV, a Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine, in Healthy Flavivirus-naïve Adult Subjects
Enrollment Status: Completed
Publish Date: January 03, 2013
Intervention Type: Biological
Study Phase: Phase 1
Phase I Evaluation of the Safety and Immunogenicity of rDEN4delta30 Lot# 109A, a Live Attenuated DEN4 Vaccine, in Healthy Flavivirus-naïve Adult Volunteers.
Enrollment Status: Completed
Publish Date: January 03, 2013
Intervention Type: Biological
Study Phase: Phase 1
Phase 1 Study of the Safety and Immunogenicity of West Nile/Dengue-4 3'delta30 Chimeric Virus Vaccine (WN/DEN4-3'delta30), a Live Attenuated Vaccine for West Nile Encephalitis
Enrollment Status: Completed
Publish Date: January 03, 2013
Intervention Type: Biological
Study Phase: Phase 1
Phase 1 Study of the Safety and Immunogenicity of rDEN3/4delta30(ME), a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 3
Enrollment Status: Completed
Publish Date: December 14, 2010
Intervention Type: Biological
Study Phase: Phase 1
Evaluation of the Safety and Immunogenicity of Heterologous Dengue Vaccine Administration in Dengue Immune Individuals
Enrollment Status: Completed
Publish Date: December 14, 2010
Intervention Type: Biological
Study Phase: Phase 1
Safety and Immunogenicity of a 2-Dose Regimen of rDEN1delta30 Dengue Serotype 1 Vaccine With Boosting at 4 Versus 6 Months
Enrollment Status: Completed
Publish Date: January 13, 2010
Intervention Type: Biological
Study Phase: Phase 1
Phase 1 Study of the Safety and Immunogenicity of rDEN4delta30-4995, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 4
Enrollment Status: Completed
Publish Date: August 07, 2009
Intervention Type: Biological
Study Phase: Phase 1
Phase 1 Study of the Safety and Immunogenicity of rDEN2/4delta30(ME), a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 2
Enrollment Status: Completed
Publish Date: January 21, 2008
Intervention Type: Biological
Study Phase: Phase 1
Phase 1 Study of the Safety and Immunogenicity of Tick-Borne Langat/Dengue 4 Chimera (LGT(TP21)/DEN4), a Live Attenuated Vaccine for Tick-Borne Encephalitis
Enrollment Status: Completed
Publish Date: January 21, 2008
Intervention Type: Biological
Study Phase: Phase 1
Phase 1 Study of the Safety and Immunogenicity of MSP1 42-C1/Alhydrogel With and Without CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria
Enrollment Status: Completed
Publish Date: January 21, 2008
Intervention Type: Biological
Study Phase: Phase 1
Phase I Study of the Safety and Immunogenicity of rDEN1delta30, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 1
Enrollment Status: Completed
Publish Date: January 18, 2008
Intervention Type: Biological
Study Phase: Phase 1
View 30 Less Clinical Trials -
146 Total Publications
Dengue: A Growing Problem With New Interventions.
Journal: Pediatrics
Published: March 11, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
MK
Dr. Michael A. Koren
Infectious Disease
Advanced
Highly rated in
4
conditions
Infectious Disease

Defense Health Agency

503 Robert Grant Ave, 
Silver Spring, MD 
 31.8 mi

Michael Koren is an Infectious Disease expert in Silver Spring, Maryland. Koren has been practicing medicine for over 13 years and is rated as an Advanced expert by MediFind in the treatment of Dengue Fever. He is also highly rated in 4 other conditions, according to our data. His top areas of expertise are Viral Hemorrhagic Fever, Yellow Fever, Dengue Fever, and Japanese Encephalitis. He is licensed to treat patients in Virginia.

AL
Dr. Arthur G. Lyons
Infectious Disease
Advanced
Highly rated in
2
conditions
Infectious Disease

Washington, DC 
 38.5 mi

Arthur Lyons is an Infectious Disease expert in Washington, Washington, D.c.. Lyons has been practicing medicine for over 28 years and is rated as an Advanced expert by MediFind in the treatment of Dengue Fever. He is also highly rated in 2 other conditions, according to our data. His top areas of expertise are Dengue Fever and Viral Hemorrhagic Fever. He is licensed to treat patients in Hawaii. Lyons is currently accepting new patients.

TB
Dr. Timothy H. Burgess
Infectious Disease
Advanced
Highly rated in
6
conditions
Infectious Disease

8901 Wisconsin Ave, 
Bethesda, MD 
 33.5 mi

Timothy Burgess is an Infectious Disease expert in Bethesda, Maryland. Burgess is rated as a Distinguished expert by MediFind in the treatment of Dengue Fever. He is also highly rated in 6 other conditions, according to our data. His top areas of expertise are Flu, COVID-19, H1N1 Influenza, and Severe Acute Respiratory Syndrome (SARS). He is licensed to treat patients in Indiana.